Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000018 ACADIA Pharmaceuticals Inc. 12/31/2019 63090034030 NUPLAZID Oral Capsule 34 MG 30 12/30/2019 155.00 3341.00 08/27/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000018 ACADIA Pharmaceuticals Inc. 12/31/2019 63090010030 NUPLAZID Oral Tablet 10 MG 30 12/30/2019 155.00 3341.00 03/23/2037 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000021 Acorda Therapeutics, Inc. 12/31/2019 10144042760 AMPYRA (dalfampridine) Extended Release 10mg Tablets / 60 Tablet Bottles 10/01/2019 242.27 2934.14 None Innovator Multiple Source Drug 98877 None AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases. None AMPYRA® has not been reformulated, but AMPYRA® is the manufacturer's primary source of revenue while revenue from a more recently-approved product, INBRIJA™, increases. None None None None None None None None None None None Regarding the inquiry relating to acquisition and patent: Regarding Patent & Patent Expiration: Acorda has filed a request with the FDA to delist the AMPYRA® patents from the Orange Book (Approved Drug Products with Therapeutic Equivalents). There are currently multiple generics on the market. Regarding Acquisition: Acorda did not acquire AMPYRA® within the previous five year period.
Rx0000157 Acrotech Biopharma LLC 06/30/2019 68152010809 BELEODAQ® (belinostat)for Injection - 500mg single-dose vial 04/01/2019 28.28 1913.58 10/27/2027 Single Source Drug 8569 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1885.30 None 2014 1500.00 None None
Rx0000157 Acrotech Biopharma LLC 09/30/2019 68152010809 BELEODAQ® (belinostat)for Injection - 500mg single-dose vial 07/15/2019 28.70 1942.28 10/27/2027 Single Source Drug 9394 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1885.30 None 2014 1500.00 None None
Rx0000157 Acrotech Biopharma LLC 12/31/2019 68152010809 BELEODAQ® (belinostat)for Injection - 500mg single-dose vial 10/01/2019 29.14 1971.42 10/27/2027 Single Source Drug 8569 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 1885.30 1776.30 2014 1500.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2019 48818000101 FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial 04/01/2019 81.64 5524.33 05/31/2025 Single Source Drug 3948 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 5442.69 None 2009 3125.00 None None
Rx0000157 Acrotech Biopharma LLC 09/30/2019 48818000101 FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial 07/15/2019 82.87 5607.20 05/31/2025 Single Source Drug 4273 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 5442.69 None 2009 3125.00 None None
Rx0000157 Acrotech Biopharma LLC 12/31/2019 48818000101 FOLOTYN® (pralatrexate injection) 20mg, 20mg/mL, 1ml Vial 10/01/2019 106.53 5713.73 05/31/2025 Single Source Drug 3948 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 5442.69 5047.97 2009 3125.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2019 48818000102 FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial 04/01/2019 163.28 11048.66 05/31/2025 Single Source Drug 2516 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 10885.38 None 2009 6250.00 None None
Rx0000157 Acrotech Biopharma LLC 09/30/2019 48818000102 FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial 07/15/2019 165.74 11214.40 05/31/2025 Single Source Drug 2667 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 10885.38 None 2009 6250.00 None None
Rx0000157 Acrotech Biopharma LLC 12/31/2019 48818000102 FOLOTYN® (pralatrexate injection) 40mg, 20mg/mL, 2ml Vial 10/01/2019 213.06 11427.46 05/31/2025 Single Source Drug 2516 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 10885.38 10095.94 2009 6250.00 None None
Rx0000157 Acrotech Biopharma LLC 06/30/2019 20536032201 MARQIBO® (vinCRIStine sulfate LIPOSOME injection) 04/01/2019 214.41 14508.62 09/25/2020 Single Source Drug 558 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 14294.21 None 2013 9750.00 None None
Rx0000157 Acrotech Biopharma LLC 12/31/2019 20536032201 MARQIBO® (vinCRIStine sulfate LIPOSOME injection) 10/01/2019 565.84 15074.46 09/25/2020 Single Source Drug 558 None None 1 None 1 03/01/2019 Spectrum Pharmaceuticals 160000000 None Acrotech Biopharma acquired the product as part of a portofolio deal involving multiple assets for $160M in upfront payments and up to $140M in additional royalties, and its acquisition price was incorporated into that deal’s overall purchase price. 14294.21 13241.25 2013 9750.00 None None
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431011001 JUXTAPID 10 MG CAPS, bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431012001 JUXTAPID 20 MG CAPS, bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431013001 JUXTAPID 30 MG CAPS, bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431014001 JUXTAPID 40 MG CAPS, bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431010501 JUXTAPID 5 MG CAPS - bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431016001 JUXTAPID 60 MG CAPS, bottle of 28 capsules 01/01/2019 3678.85 40670.85 08/19/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The drug was developed by the manufacturer therefore the acquisition related fields are blank.
Rx0000203 Aegerion Pharmaceuticals, Inc. 03/31/2019 76431021001 MYALEPT 11.3MG VIAL - 1 vial 01/01/2019 419.06 4632.82 07/17/2027 Single Source Drug None 1 None 1 None 1 01/12/2015 AstraZeneca 325000000 None None 3493.00 None 2014 3493.00 None The product was introduced to the market before it was acquired by Aegerion Pharmaceuticals which was later acquired by Amryt in 2019. The information provided in this report is the only information available to Amryt. Amryt has no knowledge of the WAC at introduction. Therefore the WAC Aegerion set after acquisition was used - 3493.00 as reported in MediSpan.
Rx0000151 Aerie Pharmaceuticals Inc. 09/30/2019 07072749725 Netarsudil ophthalmic solution 0.02%, 2.5mL bottle 09/23/2019 22.46 272.07 03/14/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Aerie Pharmaceuticals, Inc. developed Rhopressa. It is not an acquired product.
Rx0000085 Akorn Inc 03/31/2019 17478021515 Atropine Sulfate Ophth Sol 1% 10mg/mL,15mL, 1 Bottle 03/18/2019 31.09 114.83 None Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478030703 Azithromycin 1% Opth Soln 10mg, 2.5ml, 1 Bottle 03/18/2019 18.58 206.21 03/31/2019 Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478050305 Dehydrated Alcohol 0.98mL/mL, 5ml, 10 Vials 03/18/2019 261.94 1295.00 None Non-innovator Multiple Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478010610 Levofloxacin Ophth Solution 0.5%, 5ml, 1 Bottle/ EA 03/18/2019 52.39 114.89 None Non-innovator Multiple Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478070102 lndocyanine Green 25mg,10ml / Amp, 6Amp 03/18/2019 111.23 683.59 None Innovator Multiple Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478060930 Tafluprost Ophth Sol .0015%.3ml/.0045mg, .3mL-30 UD pk 03/18/2019 19.19 213.01 05/28/2029 Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 04/01/2014 Merck None 1 No comment 103.79 None 2014 103.79 None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 17478004532 Tetracaine HCI Injection 1% lOmg/mL, 2ml, 25 Ampules 03/18/2019 994.47 1898.53 None Non-innovator Multiple Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 76478000105 Timolol 0.25% Opth Solution 2.56mg/mL, 5ml, 1 Bottle 03/18/2019 11.51 127.76 None Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 76478000215 Timolol 0.5% Opth Solution 5.12mg/ml, 15ml, 1 Bottle 03/18/2019 36.74 407.89 None Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 76478000205 Timolol 0.5% Opth Solution 5.12mg/mL, 5ml, 1 Bottle 03/18/2019 12.71 141.07 None Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000085 Akorn Inc 03/31/2019 76478000210 Timolol 0.50% Opth Solution 5.12mg/ml, 10ml, 1 Bottle 03/18/2019 24.41 271.01 None Single Source Drug None 1 Cost of improvements in manufacturing process of products. None None 1 None None None None None None None None None None Patent Expiration Dates provided for products under patent as of effective date of applicable WAC increase. Information requested in Columns N-U provided for products acquired within five years of the effective date of applicable WAC increase.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004230 Irbesartan 150mg Tablet 30ct 04/17/2019 63.91 75.00 None Non-innovator Multiple Source Drug 12060 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004271 Irbesartan 150mg Tablet 500ct 04/17/2019 1068.80 1250.00 None Non-innovator Multiple Source Drug 0 1 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004290 Irbesartan 150mg Tablet 90ct 04/17/2019 191.72 225.00 None Non-innovator Multiple Source Drug 14040 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004330 Irbesartan 300mg Tablet 30ct 04/17/2019 76.15 90.00 None Non-innovator Multiple Source Drug 3828 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004371 Irbesartan 300mg Tablet 500ct 04/17/2019 1269.20 1500.00 None Non-innovator Multiple Source Drug 3984 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004390 Irbesartan 300mg Tablet 90ct 05/01/2019 228.46 270.00 None Non-innovator Multiple Source Drug 23292 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004130 Irbesartan 75mg Tablet 30ct 04/17/2019 49.46 60.00 None Non-innovator Multiple Source Drug 18744 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332004190 Irbesartan 75mg Tablet 90ct 04/17/2019 148.38 180.00 None Non-innovator Multiple Source Drug 0 1 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332005130 Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 30ct 04/08/2019 66.30 90.00 None Non-innovator Multiple Source Drug 48 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332005190 Irbesartan/Hydrochlorothiazide 150mg-12.5mg Tablet 90ct 04/08/2019 201.30 270.00 None Non-innovator Multiple Source Drug 936 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332005230 Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 30ct 04/08/2019 51.30 97.50 None Non-innovator Multiple Source Drug 10356 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 06/30/2019 62332005290 Irbesartan/Hydrochlorothiazide 300mg-12.5mg Tablet 90ct 04/08/2019 157.20 292.50 None Non-innovator Multiple Source Drug 1860 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 09/30/2019 62332004930 Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 30ct 07/15/2019 36.03 41.25 None Non-innovator Multiple Source Drug 6732 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 09/30/2019 62332004990 Losartan Potassium/Hydrochlorothiazide 100mg-12.5mg Tablet 90ct 07/15/2019 110.47 123.75 None Non-innovator Multiple Source Drug 2028 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 09/30/2019 62332005030 Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 30ct 07/15/2019 36.03 41.25 None Non-innovator Multiple Source Drug 17784 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000235 Alembic Pharmaceuticals, Inc. 09/30/2019 62332005090 Losartan Potassium/Hydrochlorothiazide 100mg-25mg Tablet 90ct 07/15/2019 110.35 123.75 None Non-innovator Multiple Source Drug 3456 None 1. Additional costs of manufacturing and production incurred by its parent Alembic Pharmaceutical, Ltd. Including a) additional cost of key starting materials used to manufacture active ingredients driven by lack of supply from China; b)costs to change Alembic Pharmaceutical, Ltd.’s manufacturing process to eliminate use of recovered solvents in manufacturing; c) additional capital investment for manufacturing of these Sartan products of approximately $200,000 to $300,000 per year; and d) longer and more stringent quality testing requirements mandated by FDA for Sartan products. 2. Any financial penalties and charges to Alembic Sales associated with a WAC price increase. 3. WAC Price of competing products. None High volume of requests received from customers to supply these products as quickly as possible. Prior to this increased volume of customer requests, Alembic Sales’ revenue and volume for all of these products was very small, driven by poor economics, and its goal was to provide sustainable supply to the market to meet the increased demand. None None None None None None None None None None None Product was not acquired. This is Alembic ANDA.
Rx0000039 Alkermes, Inc 03/31/2019 65757040103 ARISTADA 441 mg/ 1.6mL extended-release injectable suspension 02/22/2019 73.28 1294.73 10/26/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Aristada was developed in-house
Rx0000039 Alkermes, Inc 03/31/2019 65757040203 ARISTADA 662 mg/2.4mL extended-release injectable suspension 02/22/2019 110.01 1943.56 10/26/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Aristada was developed in-house
Rx0000039 Alkermes, Inc 03/31/2019 65757040303 ARISTADA 882 mg/3.2mL extended-release injectable suspension 02/22/2019 146.57 2589.46 10/26/2030 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Aristada was developed in-house
Rx0000020 Allergan 03/31/2019 00430047801 ACTONEL-150 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 17.25 369.33 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430047802 ACTONEL-150 mg-3-CAPSULE,DELAYED RELEASE 01/01/2019 51.76 1108.00 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430047207 ACTONEL-35 mg-12-CAPSULE,DELAYED RELEASE 01/01/2019 47.78 1022.92 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430047203 ACTONEL-35 mg-4-CAPSULE,DELAYED RELEASE 01/01/2019 15.93 340.98 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430047115 ACTONEL-5 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 17.08 365.56 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023350730 ACUVAIL-0.45 %-30-DROPPERETTE, SINGLE-USE DROP DISPENSER 01/01/2019 14.87 318.31 03/07/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023932110 ALPHAGAN P-0.1 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 27.74 319.78 01/10/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023932115 ALPHAGAN P-0.1 %-15-CAPSULE,DELAYED RELEASE 01/01/2019 41.62 479.74 01/10/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023932105 ALPHAGAN P-0.1 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 13.88 159.96 01/10/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023917710 ALPHAGAN P-0.15 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 29.58 340.99 01/28/2022 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023917715 ALPHAGAN P-0.15 %-15-CAPSULE,DELAYED RELEASE 01/01/2019 44.38 511.53 01/28/2022 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023917705 ALPHAGAN P-0.15 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 14.80 170.54 01/28/2022 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544007660 ANDRODERM-2 mg/24 hour-60-CAPSULE,DELAYED RELEASE 01/01/2019 53.43 615.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023599060 ANDRODERM-2 mg/24 hour-60-PATCH, TRANSDERMAL 24 HOURS 01/01/2019 53.43 615.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544007730 ANDRODERM-4 mg/24 hour-30-CAPSULE,DELAYED RELEASE 01/01/2019 53.43 615.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023599230 ANDRODERM-4 mg/24 hour-30-PATCH, TRANSDERMAL 24 HOURS 01/01/2019 53.43 615.90 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456046101 ARMOUR THYROID-120 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 13.33 153.62 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456045701 ARMOUR THYROID-15 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 5.57 64.24 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456045801 ARMOUR THYROID-30 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 6.54 75.42 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456045901 ARMOUR THYROID-60 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 7.27 83.79 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456046001 ARMOUR THYROID-90 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 11.39 131.27 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430078327 ASACOL HD-800 mg-180-CAPSULE,DELAYED RELEASE 01/01/2019 146.84 1692.50 11/15/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023590118 ASACOL HD-800 mg-180-TABLET, DELAYED RELEASE (ENTERIC COATED) 01/01/2019 146.84 1692.50 11/15/2021 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430097903 ATELVIA-35 mg-4-CAPSULE,DELAYED RELEASE 01/01/2019 12.45 266.56 01/09/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456270001 AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE 01/01/2019 31.13 358.81 06/15/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456270010 AVYCAZ-2.5 gram-1-CAPSULE,DELAYED RELEASE 01/01/2019 311.30 3588.09 06/15/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914008052 BENTYL-10 mg/mL-2-CAPSULE,DELAYED RELEASE 01/01/2019 19.63 420.29 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023031304 BLEPHAMIDE S.O.P.-10 %-0.2 %-3.5-OINTMENT (GRAM) 01/01/2019 6.80 145.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980002210 BLEPHAMIDE-10 %-0.2 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 13.59 290.98 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980002205 BLEPHAMIDE-10 %-0.2 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 6.80 145.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456141030 BYSTOLIC-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.43 143.24 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456141090 BYSTOLIC-10 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 37.28 429.71 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456140263 BYSTOLIC-2.5 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 42.21 486.53 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456140230 BYSTOLIC-2.5 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.43 143.24 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456142030 BYSTOLIC-20 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.43 143.24 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456142090 BYSTOLIC-20 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 37.28 429.71 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456140563 BYSTOLIC-5 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 42.21 486.53 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456140530 BYSTOLIC-5 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.43 143.24 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456140590 BYSTOLIC-5 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 37.28 429.71 12/17/2021 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914050156 CANASA-1,000 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 100.79 1161.78 06/06/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914050142 CANASA-1,000 mg-42-CAPSULE,DELAYED RELEASE 01/01/2019 141.11 1626.51 06/06/2028 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914017014 CARAFATE-1 gram/10 mL-420-CAPSULE,DELAYED RELEASE 01/01/2019 18.16 209.28 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914017110 CARAFATE-1 gram-100-CAPSULE,DELAYED RELEASE 01/01/2019 33.71 388.51 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456401001 CELEXA-10 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 42.40 907.71 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456402001 CELEXA-20 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 44.19 946.10 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456404001 CELEXA-40 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 46.12 987.29 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023921110 COMBIGAN-0.2 %-0.5 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 30.60 352.68 04/19/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023921115 COMBIGAN-0.2 %-0.5 %-15-CAPSULE,DELAYED RELEASE 01/01/2019 45.89 528.98 04/19/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023921105 COMBIGAN-0.2 %-0.5 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 15.30 176.33 04/19/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611803 CONDYLOX-0.5 %-3.5-CAPSULE,DELAYED RELEASE 01/01/2019 29.58 633.34 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544025524 CRINONE-4 %-1.125-CAPSULE,DELAYED RELEASE 01/01/2019 5.02 107.52 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023615108 CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE 01/01/2019 20.94 448.20 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544025612 CRINONE-8 %-1.125-CAPSULE,DELAYED RELEASE 01/01/2019 20.94 448.20 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023585318 DELZICOL-400 mg-180-CAPSULE (WITH DELAYED RELEASE TABLETS) 01/01/2019 60.58 698.31 04/13/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430375414 ESTRACE-0.01 %-42.5-CAPSULE,DELAYED RELEASE 01/01/2019 29.91 344.78 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430072024 ESTRACE-0.5 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 25.46 545.10 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430072124 ESTRACE-1 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 25.46 545.10 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430072224 ESTRACE-2 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 32.68 699.69 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456221230 FETZIMA-120 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 34.08 392.80 05/23/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456220228 FETZIMA-20 mg (2)-40 mg (26)-28-CAPSULE,DELAYED RELEASE 01/01/2019 31.81 366.62 05/23/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456222030 FETZIMA-20 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 34.08 392.80 05/23/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456224030 FETZIMA-40 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 34.08 392.80 05/23/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456228030 FETZIMA-80 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 34.08 392.80 05/23/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544095601 FIORINAL WITH CODEINE #3-30 mg-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 52.97 1133.91 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544095501 FIORINAL-50 mg-325 mg-40 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 25.27 541.03 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980022810 FML FORTE-0.25 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 14.27 305.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980022805 FML FORTE-0.25 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 7.14 152.76 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023031604 FML S.O.P.-0.1 %-3.5-OINTMENT (GRAM) 01/01/2019 7.14 152.76 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980021110 FML-0.1 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 14.27 305.53 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980021105 FML-0.1 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 7.14 152.76 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544008430 GELNIQUE-10 % (100 mg/gram)-1-CAPSULE,DELAYED RELEASE 01/01/2019 18.48 395.53 03/26/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023586111 GELNIQUE-10 % (100 mg/gram)-1-GEL IN PACKET (GRAM) 01/01/2019 18.48 395.53 03/26/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023581230 GELNIQUE-100 mg/gram per actuation (10 %)-30-GEL IN METERED-DOSE PUMP 01/01/2019 18.48 395.53 03/26/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544020431 GENERESS FE-0.8 mg-25 mcg (24)/75 mg (~24.7 mg iron)(4)-28-CAPSULE,DELAYED RELEASE 01/01/2019 22.93 490.85 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023429003 LASTACAFT-0.25 %-3-DROPS 01/01/2019 10.53 225.39 12/23/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456201001 LEXAPRO-10 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 99.54 1147.35 02/12/2023 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456202001 LEXAPRO-20 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 103.87 1197.27 02/12/2023 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456200501 LEXAPRO-5 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 95.21 1097.38 02/12/2023 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544003554 LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 65.02 749.40 03/22/2034 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023585801 LILETTA-19.5 mcg/24 hour (5 years) 52 mg-1-INTRAUTERINE DEVICE 01/01/2019 65.02 749.40 03/22/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456120130 LINZESS-145 mcg-30-CAPSULE,DELAYED RELEASE 01/01/2019 36.77 423.83 08/16/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456120230 LINZESS-290 mcg-30-CAPSULE,DELAYED RELEASE 01/01/2019 36.77 423.83 08/16/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456120330 LINZESS-72 mcg-30-CAPSULE,DELAYED RELEASE 01/01/2019 36.77 423.83 08/16/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430042014 LO LOESTRIN FE-1 mg-10 mcg (24)/10 mcg (2)/75 mg (2)-28-CAPSULE,DELAYED RELEASE 01/01/2019 61.04 703.59 02/02/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023320503 LUMIGAN-0.01 %-2.5-DROPS 01/01/2019 17.09 196.97 03/16/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023320505 LUMIGAN-0.01 %-5-DROPS 01/01/2019 34.16 393.78 03/16/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023320508 LUMIGAN-0.01 %-7.5-DROPS 01/01/2019 51.24 590.64 03/16/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430054050 MINASTRIN 24 FE-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE,DELAYED RELEASE 01/01/2019 41.49 888.13 04/06/2019 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456430001 MONUROL-3 gram-1-CAPSULE,DELAYED RELEASE 01/01/2019 7.54 86.92 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456341433 NAMENDA XR-14 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.32 464.77 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456341490 NAMENDA XR-14 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 120.97 1394.32 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456342133 NAMENDA XR-21 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.32 464.77 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456342833 NAMENDA XR-28 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.32 464.77 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456342890 NAMENDA XR-28 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 120.97 1394.32 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456340029 NAMENDA XR-7 mg (7)-14 mg (7)-21 mg (7)-28 mg (7)-28-CAPSULE,DELAYED RELEASE 01/01/2019 37.64 433.80 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456340733 NAMENDA XR-7 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.32 464.77 09/24/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456121430 NAMZARIC-14 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.14 462.66 12/05/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456122130 NAMZARIC-21 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.14 462.66 12/05/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456122830 NAMZARIC-28 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.14 462.66 12/05/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456122929 NAMZARIC-7 mg-10 mg (7)/14 mg-10 mg (7)/21 mg-10 mg(7)/28 mg-10 mg(7)-28-CAPSULE,DELAYED RELEASE 01/01/2019 37.46 431.81 12/05/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456120730 NAMZARIC-7 mg-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 40.14 462.66 12/05/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023615301 OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE 01/01/2019 3.97 84.98 04/26/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544092054 OXYTROL-3.9 mg/24 hour-1-CAPSULE,DELAYED RELEASE 01/01/2019 3.97 84.98 04/26/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023615308 OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE 01/01/2019 31.76 679.85 04/26/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544092008 OXYTROL-3.9 mg/24 hour-8-CAPSULE,DELAYED RELEASE 01/01/2019 31.76 679.85 04/26/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980018010 PRED FORTE-1 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 13.59 290.98 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980018015 PRED FORTE-1 %-15-CAPSULE,DELAYED RELEASE 01/01/2019 20.39 436.47 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980018005 PRED FORTE-1 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 6.80 145.49 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980017410 PRED MILD-0.12 %-10-CAPSULE,DELAYED RELEASE 01/01/2019 13.59 290.98 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 11980017405 PRED MILD-0.12 %-5-CAPSULE,DELAYED RELEASE 01/01/2019 6.80 145.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023006604 PRED-G-0.3 %-0.6 %-3.5-OINTMENT (GRAM) 01/01/2019 6.80 145.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023010605 PRED-G-0.3 %-1 %-5-SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 01/01/2019 6.80 145.49 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914060120 PYLERA-140 mg-125 mg-125 mg-120-CAPSULE,DELAYED RELEASE 01/01/2019 43.05 921.54 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023614730 RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.21 261.48 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544015130 RAPAFLO-4 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.21 261.48 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023614230 RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.21 261.48 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544015230 RAPAFLO-8 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 12.21 261.48 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023614290 RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 36.64 784.40 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 52544015219 RAPAFLO-8 mg-90-CAPSULE,DELAYED RELEASE 01/01/2019 36.64 784.40 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914030180 RECTIV-0.4 % (w/w)-30-CAPSULE,DELAYED RELEASE 01/01/2019 29.93 640.74 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023530105 RESTASIS MULTIDOSE-0.05 %-5.5-DROPS 01/01/2019 48.39 557.72 05/11/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023916330 RESTASIS-0.05 %-30-CAPSULE,DELAYED RELEASE 01/01/2019 24.19 278.85 08/27/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023916360 RESTASIS-0.05 %-60-CAPSULE,DELAYED RELEASE 01/01/2019 48.39 557.72 08/27/2024 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430021014 SARAFEM-10 mg-28-CAPSULE,DELAYED RELEASE 01/01/2019 27.31 584.74 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00430022014 SARAFEM-20 mg-28-CAPSULE,DELAYED RELEASE 01/01/2019 27.31 584.74 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456151060 SAVELLA-100 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 33.14 381.93 09/19/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456150055 SAVELLA-12.5 mg (5)-25 mg (8)-50 mg (42)-55-CAPSULE,DELAYED RELEASE 01/01/2019 30.37 350.10 09/19/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456151260 SAVELLA-12.5 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 33.14 381.93 09/19/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456152560 SAVELLA-25 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 33.14 381.93 09/19/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456155060 SAVELLA-50 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 33.14 381.93 09/19/2029 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023586230 TAYTULLA-1 mg-20 mcg (24)/75 mg (4)-28-CAPSULE 01/01/2019 81.10 934.74 03/29/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456040001 TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 16.67 192.12 02/10/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456040010 TEFLARO-400 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 166.68 1921.21 02/10/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456060001 TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 16.67 192.12 02/10/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456060010 TEFLARO-600 mg-1-CAPSULE,DELAYED RELEASE 01/01/2019 166.68 1921.21 02/10/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914079010 URSO FORTE-500 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 45.59 975.95 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 58914078510 URSO-250 mg-100-CAPSULE,DELAYED RELEASE 01/01/2019 25.73 550.74 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 61874010060 VIBERZI-100 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 108.85 1254.66 03/25/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 61874007560 VIBERZI-75 mg-60-CAPSULE,DELAYED RELEASE 01/01/2019 108.85 1254.66 03/25/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456110130 VIIBRYD-10 mg (7)-20 mg (23)-30-CAPSULE,DELAYED RELEASE 01/01/2019 23.62 272.24 06/05/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456111030 VIIBRYD-10 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 23.62 272.24 06/05/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456112030 VIIBRYD-20 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 23.62 272.24 06/05/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00456114030 VIIBRYD-40 mg-30-CAPSULE,DELAYED RELEASE 01/01/2019 23.62 272.24 06/05/2022 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611001 ZENPEP-10,000 unit-32,000 unit-42,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 29.07 335.02 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030602 ZENPEP-10,000 unit-34,000 unit-55,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 29.07 335.02 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611101 ZENPEP-15,000 unit-47,000 unit-63,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 41.98 483.87 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030202 ZENPEP-15,000 unit-51,000 unit-82,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 41.98 483.87 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611201 ZENPEP-20,000 unit-63,000 unit-84,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 57.02 657.27 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030302 ZENPEP-20,000 unit-68,000 unit-109,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 57.02 657.27 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611601 ZENPEP-25,000 unit-79,000 unit-105,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 70.56 813.34 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030502 ZENPEP-25,000 unit-85,000 unit-136,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 70.56 813.34 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611301 ZENPEP-3,000 unit-10,000 unit-14,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 15.41 177.63 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030402 ZENPEP-3,000 unit-10,000 unit-16,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 15.41 177.63 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611401 ZENPEP-40,000 unit-126,000 unit-168,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 112.54 1297.15 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030702 ZENPEP-40,000 unit-136,000 unit-218,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 112.54 1297.15 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 00023611501 ZENPEP-5,000 unit-17,000 unit-24,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 14.70 169.48 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000020 Allergan 03/31/2019 42865030002 ZENPEP-5,000 unit-17,000 unit-27,000 unit-100-CAPSULE,DELAYED RELEASE 01/01/2019 14.70 169.48 02/20/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None All products have been owned or launched by Allergan in the past 5 years inclusive of Actavis and Allergan who merged in 2015
Rx0000037 AMAG Pharmaceuticals, Inc. 03/31/2019 59338077501 ferumoxytol 510MG/17 mL Feraheme 510mg Each 01/01/2019 27.46 942.79 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 06/30/2019 59338077501 ferumoxytol 510MG/17 mL Feraheme 510mg Each 04/01/2019 28.28 971.07 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 09/30/2019 59338077501 ferumoxytol 510MG/17 mL Feraheme 510mg Each 07/01/2019 29.13 1000.20 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037 AMAG Pharmaceuticals, Inc. 12/31/2019 59338077501 ferumoxytol 510MG/17 mL Feraheme 510mg Each 10/01/2019 30.01 1030.21 06/30/2023 Single Source Drug None 1 Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 03/31/2019 59338077510 ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 01/01/2019 274.60 9427.90 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 06/30/2019 59338077510 ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 04/01/2019 282.80 9710.70 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037 AMAG Pharmaceuticals, Inc. 09/30/2019 59338077510 ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 07/01/2019 291.32 10002.02 06/30/2023 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. As a result of these efforts, AMAG received FDA approval for an expanded label for Feraheme in February 2018 to allow treatment of all eligible adults with iron deficiency anemia. This sNDA approval doubles the number of patients who could benefit from Feraheme to include both CKD and non-CKD patients
Rx0000037 AMAG Pharmaceuticals, Inc. 12/31/2019 59338077510 ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 10/01/2019 300.06 10302.08 06/30/2023 Single Source Drug None 1 Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory. None This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000050 Amarin Pharma, Inc. 12/31/2019 52937000120 Vascepa(Icosapent ethyl) 120 1g 12/31/2019 27.33 330.98 06/28/2033 Single Source Drug 3158163 None None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=336 VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000050 Amarin Pharma, Inc. 12/31/2019 52937000340 Vascepa(Icosapent ethyl) 240 500 mg 12/31/2019 31.97 387.24 06/28/2033 Single Source Drug 34858 None None 1 None 1 None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=337 VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels, developed, and manufactured by Amarin Pharmaceuticals.
Rx0000231 American Health Packaging 12/31/2019 68084037301 Acetaminophen & Codeine Phosphate Tablet CIII 300mg/60mg 100UD 12/13/2019 33.79 92.50 None Non-innovator Multiple Source Drug 3545 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084077725 Acetaminophen ER Tablet 650mg 30UD 12/05/2019 6.45 25.13 None Non-innovator Multiple Source Drug 3382 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084010701 Acyclovir Capsule 200mg 100UD 12/13/2019 4.67 34.08 None Non-innovator Multiple Source Drug 6413 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 60687028621 Bromocriptine Mesylate Tablet 2.5mg 30UD 03/27/2019 59.82 206.88 None Non-innovator Multiple Source Drug 3081 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084028101 Carbidopa & Levodopa ER Tablet 25mg/100mg 100UD 12/05/2019 47.29 78.44 None Non-innovator Multiple Source Drug 8151 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084024401 Clindamycin HCl Capsule 300mg 100UD 08/01/2019 19.71 110.58 None Non-innovator Multiple Source Drug 4662 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 60687042321 Clobazam Tablet CIV 10mg 30UD 12/05/2019 11.25 65.00 None Non-innovator Multiple Source Drug 0 1 Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 60687035825 Colchicine Capsule 0.6mg 30UD 11/08/2019 37.12 204.00 None Non-innovator Multiple Source Drug 3321 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084060621 Desmopressin Acetate Tablet 0.1mg 30UD 11/08/2019 13.06 56.98 None Non-innovator Multiple Source Drug 5246 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084033301 Diclofenac Sodium DR Tablet 75mg 100UD 12/05/2019 13.55 67.05 None Non-innovator Multiple Source Drug 1259 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 60687036901 Dicyclomine HCl Capsule 10mg 100UD 09/27/2019 9.57 54.94 None Non-innovator Multiple Source Drug 1743 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 60687022801 Diltiazem HCI Capsule ER 24h 300mg 100UD 09/12/2019 29.58 158.99 None Non-innovator Multiple Source Drug 2204 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68084074332 Doxycycline Capsule 100mg 20UD 03/05/2019 8.63 29.81 None Non-innovator Multiple Source Drug 14708 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084032921 Fenofibrate Capsule 200mg 30UD 12/05/2019 35.23 150.00 None Non-innovator Multiple Source Drug 1761 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68084028801 Fludrocortisone Acetate Tablet 0.1mg 100UD 03/05/2019 14.16 84.38 None Non-innovator Multiple Source Drug 16476 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084072921 Galantamine Tablet 4mg 30UD 08/01/2019 44.47 105.00 None Non-innovator Multiple Source Drug 1695 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084011201 Glipizide ER Tablet 10mg 100UD 12/05/2019 15.50 88.44 None Non-innovator Multiple Source Drug 2238 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 06/30/2019 68084029521 Glipizide ER Tablet 2.5mg 30UD 05/13/2019 4.25 34.00 None Non-innovator Multiple Source Drug 0 1 Market Conditions None No change or improvement in the drug product None None None None None None None None None None None Price increase >16% when factoring previous two years of price changes. The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68084074825 Guanfacine Tablet 1mg 30UD 03/05/2019 22.21 46.90 None Non-innovator Multiple Source Drug 8106 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 06/30/2019 68084025021 Haloperidol Tablet 20mg 30UD 05/23/2019 34.28 139.81 None Non-innovator Multiple Source Drug 4597 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 06/30/2019 60687016101 Haloperidol Tablet 5mg 100UD 05/29/2019 26.29 91.00 None Non-innovator Multiple Source Drug 12693 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084084701 Hydroxyzine Pamoate Capsule 25mg 100UD 09/27/2019 25.32 50.00 None Non-innovator Multiple Source Drug 24756 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68001037400 ISOSORBIDE DINITRATE TAB 10MG 100 03/28/2019 28.89 86.68 None Non-innovator Multiple Source Drug 0 1 Market Conditions None No change or improvement in the drug product None 02/27/2019 Blue Point Laboratories 350955 None BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product. 57.79 None 2019 57.79 None Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231 American Health Packaging 03/31/2019 68001037500 ISOSORBIDE DINITRATE TAB 20MG 100 03/28/2019 31.78 95.35 None Non-innovator Multiple Source Drug 0 1 Market Conditions None No change or improvement in the drug product None 02/27/2019 Blue Point Laboratories 448145 None BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product. 63.57 None 2019 63.57 None Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231 American Health Packaging 03/31/2019 68001033708 LISINOPRIL TAB 40 MG 1000 02/11/2019 47.30 116.36 None Non-innovator Multiple Source Drug 22870 None Market Conditions None No change or improvement in the drug product None 03/18/2019 Blue Point Laboratories 207786 None BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product. 116.36 None 2017 116.36 None Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231 American Health Packaging 03/31/2019 68001033308 LISINOPRIL TAB 5 MG 1000 02/11/2019 6.80 37.41 None Non-innovator Multiple Source Drug 22686 None Market Conditions None No change or improvement in the drug product None 03/15/2019 Blue Point Laboratories 245872 None BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product. 30.61 None 2017 30.61 None Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231 American Health Packaging 12/31/2019 68084073801 Methadone HCl Tablet CII 10mg 100UD 12/05/2019 4.38 30.26 None Non-innovator Multiple Source Drug 14073 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 60687035701 Methimazole Tablet 5mg 100UD 09/04/2019 13.35 50.00 None Non-innovator Multiple Source Drug 700 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084067601 Metoclopramide Tablet 10mg 100UD 09/04/2019 19.00 40.00 None Non-innovator Multiple Source Drug 13788 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084004001 Misoprostol Tablet 100mcg 100UD 12/05/2019 70.33 206.58 None Non-innovator Multiple Source Drug 7108 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084004101 Misoprostol Tablet 200mcg 100UD 12/05/2019 67.14 227.14 None Non-innovator Multiple Source Drug 15565 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 60687037401 Nabumetone Tablet 500mg 100UD 02/18/2019 39.11 105.00 None Non-innovator Multiple Source Drug 0 1 Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68001031800 NADOLOL TAB 40MG 100 03/28/2019 103.06 320.94 None Non-innovator Multiple Source Drug 2062 None Market Conditions None No change or improvement in the drug product None 02/04/2019 Blue Point Laboratories 444930 None BluePoint Laboratories and AHP are both owned by AmerisourceBergen - the acquisition price listed is the Q1 total for all units received within Q1 2019. AHP is the US distributor for Bluepoint product. 320.94 None 2017 320.94 None Bluepoint Laboratories is a sibling company with AHP as its US distributor and is the responsible party for distribution of their products.
Rx0000231 American Health Packaging 03/31/2019 68084059701 Nifedipine ER Tablet 30mg 100UD 03/14/2019 47.84 149.00 None Non-innovator Multiple Source Drug 14896 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68084059801 Nifedipine ER Tablet 60mg 100UD 03/14/2019 72.83 247.25 None Non-innovator Multiple Source Drug 5829 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 03/31/2019 68084060321 Nifedipine ER Tablet 90mg 30UD 03/14/2019 35.69 93.63 None Non-innovator Multiple Source Drug 8873 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 62584081201 Oxazepam Capsule CIV 10mg 100UD 12/05/2019 42.50 198.75 None Non-innovator Multiple Source Drug 2113 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 62584081301 Oxazepam Capsule CIV 15mg 100UD 12/05/2019 37.48 218.73 None Non-innovator Multiple Source Drug 4681 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 62584081401 Oxazepam Capsule CIV 30mg 100UD 12/05/2019 64.18 242.80 None Non-innovator Multiple Source Drug 1104 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084084501 Oxcarbazepine Tablet 150mg 100UD 09/04/2019 21.54 53.85 None Non-innovator Multiple Source Drug 9550 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084085301 Oxcarbazepine Tablet 300mg 100UD 09/04/2019 26.62 88.31 None Non-innovator Multiple Source Drug 16133 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084086701 Oxcarbazepine Tablet 600mg 100UD 09/04/2019 46.61 155.07 None Non-innovator Multiple Source Drug 6626 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084004601 Paroxetine HCl Tablet 30mg 100UD 12/13/2019 14.82 94.82 None Non-innovator Multiple Source Drug 783 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084063201 Potassium Chloride ER Tablet 10mEq K 100UD 12/05/2019 25.71 73.21 None Non-innovator Multiple Source Drug 21782 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 12/31/2019 68084096425 Propylthiouracil Tablet 50mg 30UD 12/05/2019 19.00 84.00 None Non-innovator Multiple Source Drug 4089 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 60687023101 Sertraline Tablet 25mg 100UD 09/04/2019 11.23 37.43 None Non-innovator Multiple Source Drug 20735 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 60687024201 Sertraline Tablet 50mg 100UD 09/04/2019 12.52 39.19 None Non-innovator Multiple Source Drug 91066 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084034401 Topiramate Tablet 100mg 100UD 08/01/2019 22.46 47.46 None Non-innovator Multiple Source Drug 22870 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231 American Health Packaging 09/30/2019 68084034201 Topiramate Tablet 25mg 100UD 08/01/2019 12.76 29.76 None Non-innovator Multiple Source Drug 32279 None Market Conditions None No change or improvement in the drug product None None None None None None None None None None None The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128 American Regent 09/30/2019 00517065001 Ferric Carboxymaltose 750 MG/15ML Solution 15 ML UD 07/01/2019 31.29 1074.25 02/15/2028 Single Source Drug 183439 None American Regent’s US Standards of Business Conduct (available at https://dsi.com/documents/376460/376852/DSI_SOBC.pdf/248ffd7a-3614-e6cc-bf02-4dd99641a79b) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition None None 1 None None None None None None None None None None Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000069 Amgen 03/31/2019 58406042541 ''ENBREL 25 mg (1mL) VIAL (EA), 1 pk'' 01/17/2019 37.76 646.76 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406042534 ''ENBREL 25 mg (1mL) VIAL (EA), 4 pk'' 01/17/2019 151.03 2587.03 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406045501 ''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 1 pk'' 01/17/2019 37.76 646.76 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406045504 ''ENBREL 25 mg/0.5mL (0.51mL) SYRINGE (mL), 4 pk'' 01/17/2019 151.03 2587.03 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406043501 ''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk'' 01/17/2019 75.52 1293.52 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406044501 ''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 1 pk'' 01/17/2019 75.52 1293.52 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406043504 ''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk'' 01/17/2019 302.06 5174.06 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 58406044504 ''ENBREL 50 mg/mL (0.98mL) SYRINGE (mL), 4 pk'' 01/17/2019 302.06 5174.06 04/24/2029 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 76075010201 ''KYPROLIS 30 mg (2 mg/mL) VIAL (EA), 1 pk'' 01/17/2019 33.81 1160.83 12/07/2027 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 76075010101 ''KYPROLIS 60 mg VIAL (EA), 1 pk'' 01/17/2019 67.62 2321.66 12/07/2027 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 55513022101 ''NPLATE 250 mcg (0.5mL) VIAL (EA), 1 pk'' 01/17/2019 54.13 1858.58 01/19/2022 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Not acquired within the last five years
Rx0000069 Amgen 03/31/2019 55513022201 ''NPLATE 500 mcg (1.0mL) VIAL (EA), 1 pk'' 01/17/2019 108.26 3717.16 01/19/2022 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Developed by Amgen
Rx0000069 Amgen 03/31/2019 55513071001 ''PROLIA 60 mg (1.0mL) SYRINGE (mL), 1 pk'' 01/17/2019 35.51 1219.06 02/19/2025 Single Source Drug None 1 "Amgen's sense of overall societal responsibility shapes our pricing decisions, which are guided by four principles of responsible pricing: Captures the value of the product: We will set prices for our therapies based on their full value, capturing all clinical, humanistic, and economic benefits; Funds continued scientific innovation: Our pricing will support aggressive investment in the discovery of innovative medicines to treat grievous illnesses; Ensures patient access: Our pricing will balance affordability and availability of patient assistance programs to help ensure patient access to our medicines; Reflects market dynamics: We will manage price in response to competition and evolving reimbursement" None None 1 None None None None None None None None None None Developed by Amgen
Rx0000122 Amneal Pharmaceuticals 03/31/2019 53746066901 Acebutolol HCl Oral Capsule 200 MG 100 02/06/2019 40.90 65.00 None Non-innovator Multiple Source Drug 105216 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 65162066910 Acebutolol HCl Oral Capsule 200 MG 100 01/25/2019 40.90 65.00 None Non-innovator Multiple Source Drug 11383 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 53746067001 Acebutolol HCl Oral Capsule 400 MG 100 02/06/2019 55.82 86.00 None Innovator Multiple Source Drug 20151 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 65162067010 Acebutolol HCl Oral Capsule 400 MG 100 01/25/2019 55.82 86.00 None Innovator Multiple Source Drug 11172 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846020101 Activella (estradiol/norethindrone acetate) Tablets 0.5mg/.01mg 1 Dial x 28 tabs 01/04/2019 23.03 255.61 None Innovator Multiple Source Drug 8952 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846020201 Activella (estradiol/norethindrone acetate) Tablets 1.0mg/.05mg 1 Dial x 28 tabs 01/04/2019 25.31 280.95 None Innovator Multiple Source Drug 7957 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 52054055022 Albenza Oral Tablet 200 MG 2Tabs 01/04/2019 43.72 485.34 None Innovator Multiple Source Drug 316688 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 52054051309 Dexedrine Oral Capsule Extended Release 24 Hour 10 MG 90 caps 01/04/2019 190.05 2109.72 None Innovator Multiple Source Drug 2649 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 52054051409 Dexedrine Oral Capsule Extended Release 24 Hour 15 MG 90 caps 01/04/2019 190.05 2109.72 None Innovator Multiple Source Drug 4223 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 52054051209 Dexedrine Oral Capsule Extended Release 24 Hour 5 MG 90 caps 01/04/2019 190.05 2109.72 None Innovator Multiple Source Drug 515 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 65162071110 Guanfacine HCl Oral Tablet 1 MG 100 02/06/2019 35.60 56.00 None Innovator Multiple Source Drug 372489 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 65162071310 Guanfacine HCl Oral Tablet 2 MG 100 02/06/2019 58.40 87.00 None Non-innovator Multiple Source Drug 109752 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 53746046605 Ibuprofen Oral Tablet 800 MG 500 03/28/2019 11.75 80.25 None Non-innovator Multiple Source Drug 194 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 65162046650 Ibuprofen Oral Tablet 800 MG 500 03/28/2019 11.75 80.25 None Non-innovator Multiple Source Drug 237540 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846030115 Nizatidine Oral Solution 15mg/mL 480 Bottle 01/04/2019 45.65 506.78 None Non-innovator Multiple Source Drug 7206 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846088201 Prandin® (repaglinide tablets) 1mg 100 Tabs 01/04/2019 71.40 792.64 None Non-innovator Multiple Source Drug 5667 None Manufacturing costs and market conditions require increase to remain on market None None 1 05/07/2018 Gemini Laboratories, LLC None None Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000 656.26 625.61 2013 339.25 None Column 12 Blank - No change to the product
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846088401 Prandin® (repaglinide tablets) 2mg 100 Tab 01/04/2019 71.40 792.64 None Non-innovator Multiple Source Drug 9733 None Manufacturing costs and market conditions require increase to remain on market None None 1 05/07/2018 Gemini Laboratories, LLC None None Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000 656.26 625.61 2013 339.25 None Column 12 Blank - No change to the product
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846050101 Pyridium® (phenazopyridine HCL) 100mg 100 Tab 01/04/2019 71.40 443.43 None Non-innovator Multiple Source Drug 2557 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 60846050201 Pyridium® (phenazopyridine HCL) 200mg 100 Tab 01/04/2019 51.36 570.13 None Non-innovator Multiple Source Drug 3459 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 64896066101 Rytary 23.75mg/95mg ER Cap 100ct 01/04/2019 28.88 320.56 12/26/2028 Single Source Drug 206350 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 64896066201 Rytary 36.25mg/145mg ER Cap 100ct 01/04/2019 28.88 320.56 12/26/2028 Single Source Drug 205662 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 64896066301 Rytary 48.75mg/195mg ER Cap 100ct 01/04/2019 28.88 320.56 12/26/2028 Single Source Drug 233657 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 03/31/2019 64896066401 Rytary 61.25mg/245mg ER Cap 100ct 01/04/2019 36.28 402.79 12/26/2028 Single Source Drug 100797 None Manufacturing costs and market conditions require increase to remain on market None None 1 None None None None None None None None None None Column 12 Blank - No change to the product Columns 14 -22 Blank - Products were not acquired from another company.
Rx0000122 Amneal Pharmaceuticals 06/30/2019 65162055650 Temazepam Oral Capsule 15 MG 500 05/08/2019 37.30 64.30 None Non-innovator Multiple Source Drug 0 1 Manufacturing costs and market conditions require increase to remain on market None No change None None None None None None None None None None None Product not acquired from another company. No changes were made to the product .This was a relaunch so there was no unit sales volume during this time frame.
Rx0000122 Amneal Pharmaceuticals 06/30/2019 65162055750 Temazepam Oral Capsule 30 MG 500 05/08/2019 42.25 76.90 None Non-innovator Multiple Source Drug 0 1 Manufacturing costs and market conditions require increase to remain on market None No change None None None None None None None None None None None Product not acquired from another company. No changes were made to the product. This was a relaunch so there was no unit sales volume during this time frame.
Rx0000271 Apotex Corp 06/30/2019 60505058204 MOXIFLOXACIN HCL OP/SLN 0.5% 3ML 04/11/2019 33.47 66.94 None Non-innovator Multiple Source Drug 2099287 None None 1 None 1 None None None None None None None None None None None
Rx0000132 Arbor Pharmaceuticals, LLC 12/31/2019 53451010301 HORIZANT Oral Tablet Extended Release 300 MG, 30 tablets in a bottle 10/01/2019 23.31 411.84 06/10/2029 Single Source Drug 59056 None Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics None None 1 07/05/2016 Xenoport, Inc. 467000000 None Price was for both product strengths and additional IP and assets 330.40 280.00 2014 162.07 None All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000132 Arbor Pharmaceuticals, LLC 12/31/2019 53451010101 HORIZANT Oral Tablet Extended Release 600 MG, 30 tablets in a bottle 10/01/2019 23.31 411.84 06/10/2029 Single Source Drug 215303 None Increases in rate of inflation, continued investment in innvotion, post-marketing regulatory commitments and requiremens, ongoing pharmacovigilance, market conditions and dynamics None None 1 07/05/2016 Xenoport, Inc. 467000000 None Price was for both product strengths and additional IP and assets 330.40 280.00 2011 99.00 None All information is provided by Arbor to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Pricing for 2011 is based on information that Arbor obtained in conjunction with the acquisition of Horizant based on publicly available information available at the time. That information is no longer available and Arbor is relying on its records from that time in making this submission. Arbor provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Arbor does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Arbor or any of its affiliates now or in the future. Arbor, on behalf of itself and affiliates, expressly reserves all such rights. Arbor believes that this submission and of all Arbor related information set forth in this submission is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Arbor’s related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Arbor is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000274 Artesa Labs, LLC 12/31/2019 57883040105 Keralac Cream, (urea 47%), Cream, 142 g 12/19/2019 40.03 693.00 None Innovator Multiple Source Drug 4098 None Raw materials, regulations None None 1 08/01/2017 Mission Pharmacal Company None 1 None 594.15 None 2014 395.00 None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893031210 MimyX Cream, n/a, Cream, 100 g 12/19/2019 30.00 520.00 None Single Source Drug 8772 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893031060 Nolix Cream, (flurandrenolide 0.05%), Cream, 120 g 12/19/2019 54.82 956.00 None Non-innovator Multiple Source Drug 2070 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893031112 Nolix Lotion, (flurandrenolide 0.05%), Lotion, 120 mL 12/19/2019 42.12 729.00 None Non-innovator Multiple Source Drug 3342 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57883040210 Plexion Cleanser, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cleanser, 285 g 12/19/2019 40.03 693.00 None Innovator Multiple Source Drug 65946 None Raw materials, regulations None None 1 08/01/2017 Mission Pharmacal Company None 1 None 594.15 None 2014 395.00 None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57883040460 Plexion Cleansing Cloths, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cloths, 60 ct. (4 g each) 12/19/2019 42.82 752.00 None Single Source Drug 5964 None Raw materials, regulations None None 1 08/01/2017 Mission Pharmacal Company None 1 None 645.30 None 2014 395.00 None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57883040302 Plexion Cream, (sodium sulfacetamide 9.8%, sulfur 4.8%), Cream, 57 g 12/19/2019 36.33 641.00 None Innovator Multiple Source Drug 8168 None Raw materials, regulations None None 1 08/01/2017 Mission Pharmacal Company None 1 None 550.20 None 2014 435.00 None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57883040502 Plexion Lotion, (sodium sulfacetamide 9.8%, sulfur 4.8%), Lotion, 57 g 12/19/2019 39.93 699.00 None Innovator Multiple Source Drug 6918 None Raw materials, regulations None None 1 08/01/2017 Mission Pharmacal Company None 1 None 599.70 None 2014 435.00 None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893030399 Riax Foam 5.5%, (benzoyl peroxide 5.5%), Form, 100 g 12/19/2019 30.87 543.00 None Single Source Drug 4176 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893030499 Riax Foam 9.5%, (benzoyl peroxide 9.5%), Form, 100 g 12/19/2019 30.87 543.00 None Single Source Drug 6246 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893030006 SelRx Shampoo, (selenium sulfide 2.3%), Shampoo, 180 mL 12/19/2019 34.72 604.00 None Innovator Multiple Source Drug 7240 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893030108 Utopic Cream, (urea 41%), Cream, 227 g 12/19/2019 49.96 883.00 None Innovator Multiple Source Drug 7524 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000274 Artesa Labs, LLC 12/31/2019 57893030230 Vytone Cream, (hydrocortisone acetate 1.9%, iodoquinol 1%), 30 ct. (2 g each) 12/19/2019 48.43 854.00 None Innovator Multiple Source Drug 9636 None Raw materials, regulations None None 1 None None None None None None None None None None None
Rx0000147 ASCEND Therapeutics US, LLC 12/31/2019 17139040004 Binosto (alendronate sodium) Effervescent tablet for oral solution, 70mg, 4 tablets in 1 carton 11/27/2019 98.40 300.00 08/11/2023 Single Source Drug None 1 None 1 None 1 09/15/2019 Mission Pharmacal Company None 1 None 201.60 201.60 2012 140.00 None None
Rx0000075 Assertio Therapeutics, Inc. 03/31/2019 13913001201 Cambia (diclofenac potassium), 50MG, Oral, 1 Packet 02/08/2019 6.81 75.62 06/16/2026 Single Source Drug 1139039 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past 5 years
Rx0000075 Assertio Therapeutics, Inc. 03/31/2019 13913000419 Gralise (gabapentin), 300MG, Oral Tablet, 90 Ct Bottle 02/08/2019 75.62 839.42 02/26/2024 Single Source Drug 1969210 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past 5 years
Rx0000075 Assertio Therapeutics, Inc. 03/31/2019 13913000519 Gralise (gabapentin), 600MG, Oral Tablet, 90 Ct Bottle 02/08/2019 75.62 839.42 02/26/2024 Single Source Drug 15463198 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past 5 years
Rx0000075 Assertio Therapeutics, Inc. 03/31/2019 13913000812 Zipsor (diclofenac potassium), 25MG, Oral Capsule, 100 Ct Bottle 02/08/2019 128.73 1429.07 02/24/2029 Single Source Drug 2365310 None None 1 None 1 None None None None None None None None None None This drug was not acquired in the past 5 years
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469032014 CRESEMBA®186mg 14 Capsules 01/08/2019 73.36 1295.91 10/31/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469052014 CRESEMBA®186mg 14 Capsules 01/08/2019 73.36 1295.91 10/31/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469042099 CRESEMBA®372mg Vial 01/08/2019 17.85 315.39 10/31/2020 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260171 Myrbetriq®25mg 100 Tablet 01/08/2019 105.77 1280.98 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260130 Myrbetriq®25mg 30 Tablet 01/08/2019 31.73 384.29 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260190 Myrbetriq®25mg 90 Tablet 01/08/2019 95.19 1152.87 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260271 Myrbetriq®50mg 100 Tablet 01/08/2019 105.77 1280.98 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260230 Myrbetriq®50mg 30 Tablet 01/08/2019 31.73 384.29 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469260290 Myrbetriq®50mg 90 Tablet 01/08/2019 95.19 1152.87 10/30/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469060773 Prograf®0.5mg 100 Capsules 01/08/2019 2.98 301.62 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469061711 Prograf®1mg 100 Capsules 01/08/2019 5.97 603.24 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469061773 Prograf®1mg 100 Capsules 01/08/2019 5.97 603.24 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469301601 Prograf®5mg 10 1ML Ampules 01/08/2019 20.58 2079.09 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469065711 Prograf®5mg 100 Capsules 01/08/2019 29.87 3016.22 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469065773 Prograf®5mg 100 Capsules 01/08/2019 29.87 3016.22 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015152 VESIcare®10mg 100 Tablet 01/08/2019 72.73 1285.03 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015101 VESIcare®10mg 30 Tablet 01/08/2019 21.82 385.51 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015103 VESIcare®10mg 90 Tablet 01/08/2019 65.46 1156.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015052 VESIcare®5mg 100 Tablet 01/08/2019 72.73 1285.03 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015001 VESIcare®5mg 30 Tablet 01/08/2019 21.82 385.51 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 51248015003 VESIcare®5mg 90 Tablet 01/08/2019 65.46 1156.53 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000048 Astellas Pharma US, Inc. 03/31/2019 00469012599 XTANDI®40mg 120 Capsules 01/08/2019 643.41 11548.60 08/13/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 22, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-21 are intentionally left blank.
Rx0000015 AstraZeneca 03/31/2019 00310621030 Farxiga 10mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 1289346480 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 None 2014 289.20 None None
Rx0000015 AstraZeneca 03/31/2019 00310620530 Farxiga 5mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 599751771 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None 02/01/2014 Bristol-Myers Squibb 2700000000 None AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred. 289.20 None 2014 289.20 None None
Rx0000015 AstraZeneca 03/31/2019 00310628030 Xigduo XR 10-1000mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 129626100 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015 AstraZeneca 03/31/2019 00310627030 Xigduo XR 10-500mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 13322599 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015 AstraZeneca 03/31/2019 00310626060 Xigduo XR 5-1000mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 212483946 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000015 AstraZeneca 03/31/2019 00310625030 Xigduo XR 5-500mg 01/01/2019 27.87 492.41 10/04/2025 Single Source Drug 22269231 None AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. None AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed. None None None None None None None None None None None AstraZeneca developed this NDC, it was not acquired within the last five years.
Rx0000058 Avanir Pharmaceuiticals 06/30/2019 64597030160 NUEDEXTA (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg), Bottles of 60 capsules 05/01/2019 76.00 1174.00 08/13/2026 Single Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None NOTE: columns 14-22 are intentionally blank since our product does not meet the requirements for completing these columns.
Rx0000108 AvKare 12/31/2019 50268068515 Prochlorperazine Maleate 10 MG Tablet 50 EA UD 10/29/2019 30.22 73.93 None Non-innovator Multiple Source Drug 1578 None Increase in Cost of Goods None There was no significant changes or improvements to this drug None None None None None None None None None None None This drug was not acquired
Rx0000108 AvKare 12/31/2019 50268068415 Prochlorperazine Maleate 5 MG Tablet 50 EA UD 10/29/2019 25.90 67.14 None Non-innovator Multiple Source Drug 1236 None Increase in Cost of Goods None There was no significant changes or improvements to this drug None None None None None None None None None None None This drug was not acquired